Absence of a significant interaction between a Haemophilus influenzae conjugate vaccine combined with a diphtheria toxoid, tetanus toxoid and acellular pertussis vaccine in the same syringe and inactivated polio vaccine.
BACKGROUND
We compared the antibody response to Haemophilus influenzae type b capsular polysaccharide (PRP) after three doses of a diphtheria toxoid, tetanus toxoid and acellular pertussis vaccine (DTaP) combined with a PRP-tetanus conjugate (PRP-T) in infants randomized to receive oral polio vaccine (OPV) or inactivated polio vaccine (IPV). The polio vaccine was given separately at the same visit.


METHODS
Three hundred fifty-six infants from pediatric practices in suburban Chicago and New Orleans were randomized into two groups. Group A received OPV at 2 and 4 months of age; Group B received IPV at 2 and 4 months of age. Both groups received DTaP/PRP-T at 2, 4 and 6 months of age and hepatitis B vaccine at 2 and 4 months of age. A serum sample was obtained before immunization (age 2 months) and 1 month after 3 doses of DTaP/PRP-T (age 7 months). Sera were assayed for antibody responses to all relevant vaccine antigens.


RESULTS
No significant vaccine antigen interference was found when polio immunization was provided by IPV or OPV for anti-PRP, diphtheria, tetanus or pertussis antibodies. OPV recipients had a significantly higher mean antibody response to serotype 1 (P = 0.03) and 2 (P = 0.0001) poliovirus.


CONCLUSIONS
Whether polio immunization was accomplished with IPV or OPV did not significantly influence the antibody responses in sera obtained at 7 months of age for anti-PRP, anti-diphtheria and anti-tetanus toxoid antibodies and antibodies to pertussis antigens, when DTaP/PRP-T was given in the primary series.
Daum
R S
RS
Department of Pediatric Infectious Diseases, The University of Chicago, IL, USA.
Zenko
C E
CE
Given
G Z
GZ
Ballanco
G A
GA
Parikh
H
H
Vidor
E
E
Liu
X
X
D000907:Antibodies, Bacterial / Q000032:analysis / Q000276:immunology*; D000914:Antibodies, Viral / Q000032:analysis / Q000276:immunology*; D004165:Diphtheria / Q000276:immunology / Q000517:prevention & control; D022681:Diphtheria-Tetanus-acellular Pertussis Vaccines / Q000008:administration & dosage*; D005260:Female; D005500:Follow-Up Studies; D018073:Haemophilus Vaccines / Q000008:administration & dosage*; D006801:Humans; D007109:Immunity / Q000502:physiology*; D007115:Immunization Schedule; D007223:Infant; D007273:Injections, Intramuscular; D008297:Male; D011051:Poliomyelitis / Q000276:immunology / Q000517:prevention & control; D011054:Poliovirus Vaccine, Inactivated / Q000008:administration & dosage*; D011055:Poliovirus Vaccine, Oral / Q000008:administration & dosage*; D013742:Tetanus / Q000276:immunology / Q000517:prevention & control; D017778:Vaccines, Combined / Q000008:administration & dosage; D014917:Whooping Cough / Q000276:immunology / Q000517:prevention & control
D000907:Antibodies, Bacterial; D000914:Antibodies, Viral; D022681:Diphtheria-Tetanus-acellular Pertussis Vaccines; D018073:Haemophilus Vaccines; D011054:Poliovirus Vaccine, Inactivated; D011055:Poliovirus Vaccine, Oral; D017778:Vaccines, Combined